WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced that Jay Dixon, senior vice president of global quality and compliance at PPD, was elected to the board of directors of the North Carolina Biosciences Organization (NCBIO), the trade association for the state’s bioscience industry.
“Jay brings a wealth of experience to the board, particularly in the area of clinical development,” said Sam Taylor, president of NCBIO. “Jay has worked with NCBIO on a number of important projects and we look forward to bringing his experience and insights to the NCBIO board of directors.”
Dixon, a seasoned executive with nearly 30 years of experience in the contract research organization (CRO), pharmaceutical and biotechnology industries, joins 14 bioscience industry leaders who were elected or re-elected to the NCBIO board on Oct. 22. Board terms are three years.
At PPD, Dixon is responsible for overseeing strategy and execution of the company’s global quality function, including clinical and laboratory quality assurance, regulatory compliance, risk management, policy and procedure management and quality management systems. He holds a bachelor’s degree in biology from Campbell University.
“With North Carolina as home to PPD’s worldwide headquarters and to thousands of talented professionals helping our clients deliver life-changing medicines, we understand the value of effective public policy in nurturing the state’s research ecosystem,” Dixon said. “NCBIO has been hard at work advancing this goal for more than 20 years. I’m honored to serve on the board of NCBIO and to support its mission of promoting the growth and development of North Carolina’s biosciences industry.”
Founded in 1994 and headquartered in Research Triangle Park, North Carolina, NCBIO advocates for state and federal public policies that encourage the growth of life science companies, support the development of a strong life science workforce and promote research and technology transfer at universities and other institutions.
NCBIO has nearly 150 members, including pharmaceutical research and manufacturing companies, medical device firms, contract research organizations, emerging businesses, venture investors, universities and service companies. Together, these companies comprise one of the largest state life science clusters in the nation. Visit ncbioscience.net for more information about NCBIO.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 14,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about executive involvement in external boards contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.